ReviewCNS drugs2018
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
Review in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.BMC research notes · 2019Pooled it
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.Journal of neurology · 2020Trial
- Eomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy.Brain communications · 2025Article
- The role of CD56Journal of neuroinflammation · 2024Review
- A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy.Cureus · 2024Article
- Alemtuzumab induced acquired hemophilia A in multiple sclerosis: a case report.Annals of hematology · 2023Article
- Synergy between health technology assessments and clinical guidelines for multiple sclerosis.Clinical and translational science · 2023Article
- Fingolimod induced fulminant liver failure requiring liver transplantation: A case report.Hepatology forum · 2023Article
- Article
- The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study.Journal of clinical medicine · 2022Article
- Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.CNS drugs · 2022Review
- Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.Pharmaceutics · 2022Article
- Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.Journal of neurology · 2022Article
- Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination.Therapeutic advances in neurological disorders · 2022Article
- Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination.Frontiers in immunology · 2022Article
- Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.Frontiers in pharmacology · 2022Article
- Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report.Clinical case reports · 2022Article
- Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia.International journal of environmental research and public health · 2021Article
- Association between multiple sclerosis and dietary patterns based on the traditional concept of food nature: a case-control study in Iran.BMC neurology · 2021Article
- Clinical translation of immunomodulatory therapeutics.Advanced drug delivery reviews · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis treatment faces tremendous changes as a result of the approval of new medications. The new medications have differing safety considerations and risks after long-term treatment, which are important for treating physicians to optimize and individualize multiple sclerosis care. Since the approval of the first multiple sclerosis capsule, fingolimod, the armamentarium of multiple sclerosis therapy has grown with the orally available medications dimethyl fumarate and teriflunomide. Fingolimod is mainly associated with cardiac side effects, dimethyl fumarate with bowel symptoms. Several reports about progressive multifocal leukoencephalopathy as a result of dimethyl fumarate or fingolimod therapy raised the awareness of fatal opportunistic infections. Alemtuzumab, a CD52-depleting antibody, is highly effective in reducing relapses but leads to secondary immunity with mainly thyroid disorders in about 30% of patients. Development of secondary B-cell-mediated disease might also be a risk of this antibody. The follow-up drug of the B-cell-depleting antibody rituximab, ocrelizumab, is mainly associated with infusion-related reactions; long-term data are scarce. The medication daclizumab high yield process, acting via the activation of CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.